trending Market Intelligence /marketintelligence/en/news-insights/trending/JjtTDO6m37Xw0Vg2TBw7PA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Approvals for Merck & Co., Astellas; designations for AstraZeneca, BridgeBio

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Approvals for Merck & Co., Astellas; designations for AstraZeneca, BridgeBio

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Jan. 10.

Approvals

* Merck & Co. Inc.'s Keytruda, as a single therapy for bladder cancer patients who are unresponsive to immunotherapy known as Bacillus Calmette-Guerin and who are ineligible or chose to not have their bladders surgically removed.

* Astellas Pharma Inc.'s Mycamine for candidemia, acute disseminated candidiasis, candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination, in children younger than 4 months.

* Blueprint Medicines Corp.'s Ayvakit, for patients with gastrointestinal stromal tumor who have a specific mutation of the platelet-derived growth factor receptor gene.

* Terumo Corp.'s Fred system, to treat brain aneurysms. The device was granted premarket approval.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* AstraZeneca PLC's Farxiga, or dapagliflozin, to lessen the risk of cardiovascular death or the worsening of heart failure in adults with reduced ejection fraction, with or without type 2 diabetes.

Fast track

* BridgeBio Pharma Inc.'s infigratinib, as initial treatment for adult patients of a form of cholangiocarcinoma that spreads across tissue and cannot be treated surgically. The medicine also received the regulator's orphan-drug tag.

Orphan drug

* Intrexon Corp.'s PRGN-3006, for relapsed or refractory acute myeloid leukemia.

* Cellectar Biosciences Inc.'s CLR 131 for treating multiple types of cancers including lymphoplasmacytic lymphoma, also known as Waldenstrom macroglobulinemia.